RAD51C has been recently shown to confer moderate risk for breast (relative risk (RR) = 1.99, 95% CI: 1.39–2.85) and high risk for ovarian cancers (RR = 7.55, 95% CI: 5.6–10.19) [64]; however, there have only been observational studies so far for EC [7,65]. The gene discussed is RAD51C; the disease is ovarian cancer.